Our Portfolio

We partner with the best innovators in biotech

Together with our business acumen, we partner with young companies and entrepreneurs to support breakthrough therapeutics, diagnostics, and digitally-enabled healthcare to improve the practice of medicine.

 
Our Portfolio - Monograph

Human Immunology Biosciences (HIBio) is a US-based precision immunology company leveraging human genetics to deliver patient-targeted approaches to autoimmune disorders that was made on August 2, 2021. HIBio is a new company that Monograph is co-incubating with Arch Venture Partners with Monograph partner Travis Murdoch as interim CEO. Monograph co-led the Series A financing round in August 2021.

View site

Our Portfolio - Monograph

AviadoBio is a UK-based gene therapy company with a program to treat an inherited form of frontotemporal dementia using pioneering novel routes of administration. Monograph co-led the Series A financing round with NEA in November 2021.

View site

Our Portfolio - Monograph

Ascend is a UK-based gene and cell therapy contract development and manufacturing organisation with differentiated offering in adeno-associated virus technologies to meet an underserved European market that was made on December 29, 2021. Ascend is a Monograph build with partner Tim Funnell as interim CEO. Monograph seeded Ascend in December 2021.

View site

Our Portfolio - Monograph

Exited August 2022

Gilead Sciences to Acquire MiroBio for approx $405 million

MiroBio is a therapeutics company developing checkpoint agonist antibodies, a new class of therapies designed to restore immune balance and treat autoimmune disease. This work is based on 15 years of research from the University of Oxford. Monograph participated in the Series B financing round in June 2022.

 

View site